The company said its testing services revenues for the quarter rose nearly 120 percent year over year.
The company is currently conducting clinical studies to validate AlloSure's technology — which underlies its kidney transplant test — in lung transplant patients.
The investment bank said the company is strongly positioned as a leader in the transplant diagnostics market with tests that serve an unmet need.
A team led by researchers at the NHLBI are testing the efficacy of measuring ddcfDNA in blood as a biomarker of chronic rejection for lung transplants.
The company said 100 US transplant centers provided its AlloSure kidney transplant test to almost 3,400 patients in Q4.
The index's 13 percent gain was below the 39 percent surge of 2017 but occurred despite the poor performance of index stocks in December.
The firm intends to use the proceeds for working capital, general corporate purposes and the potential repayment of indebtedness.
The company said testing services revenues more than doubled during the quarter as its AlloSure kidney transplant diagnostic continued to penetrate the market.
The company said it intends to use the proceeds for working capital and corporate purposes, including capital expenditures, R&D, clinical trials, and more.
The investment bank said it is encouraged by the company's strong pipeline and position among its competitors but sees further upside for its stock.
Two researchers are calling for education for scientists on defending facts.
Researchers were among those who marched in London this weekend to call for another vote on Brexit.
Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant.
In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.